Washington, D.C., March 8, 2017—The National Organization for Rare Disorders (NORD), the leading independent nonprofit organization representing the 30 million Americans with rare diseases, issued the following statement in advance… Read more
Catalyst Pharmaceuticals Announces FDA Orphan Drug Designation of Firdapse for the Treatment of Myasthenia Gravis
CORAL GABLES, Fla., Sept. 02, 2016 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today… Read more
Actinium Pharmaceuticals Announces Submission of EU Orphan Designation Application for Actimab-A
– Actimab-A has received Orphan Drug Designation in the U.S. – Orphan Designation in the EU can result in regulatory assistance, reduced fees and 10 years of market exclusivity NEW… Read more